{"organizations": [], "uuid": "7ebec54fb0ed67ee1d58b4bbfe8d085f21867188", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/futures", "section_title": "Futures - Markets | Reuters.com", "url": "https://www.reuters.com/article/brief-salix-provides-update-on-fda-submi/brief-salix-provides-update-on-fda-submission-for-plenvu-idUSASB0C520", "country": "US", "domain_rank": 408, "title": "Salix Provides Update On FDA Submission For Plenvu", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.227, "site_type": "news", "published": "2018-02-09T22:13:00.000+02:00", "replies_count": 0, "uuid": "7ebec54fb0ed67ee1d58b4bbfe8d085f21867188"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-salix-provides-update-on-fda-submi/brief-salix-provides-update-on-fda-submission-for-plenvu-idUSASB0C520", "ord_in_thread": 0, "title": "Salix Provides Update On FDA Submission For Plenvu", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda submission for plenvu feb", "sentiment": "negative"}, {"name": "salix", "sentiment": "negative"}, {"name": "reuters) - valeant pharmaceuticals international inc", "sentiment": "neutral"}, {"name": "fda", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}, {"name": "salix pharmaceuticals", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 9, 2018 / 2:13 PM / Updated 12 minutes ago BRIEF-Salix Provides Update On FDA Submission For Plenvu Reuters Staff \nFeb 9 (Reuters) - Valeant Pharmaceuticals International Inc : * SALIX PROVIDES UPDATE ON FDA SUBMISSION FOR PLENVU \n* SALIX PHARMACEUTICALS- PDUFA ACTION DATE HAS BEEN EXTENDED TO ALLOW FDA MORE TIME TO REVIEW ADDITIONAL DATA THAT WAS RECENTLY PROVIDED AT ITS REQUEST \n* SALIX PHARMACEUTICALS - FDA EXTENDED PDUFA ACTION DATE FOR REVIEW OF NDA FOR PLENVU (NER1006) BY THREE MONTHS TO MAY 13 Source text for Eikon: Further company coverage:", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-09T22:13:00.000+02:00", "crawled": "2018-02-09T16:20:38.003+02:00", "highlightTitle": ""}